You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 19, 2024

UMBRALISIB TOSYLATE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for umbralisib tosylate and what is the scope of patent protection?

Umbralisib tosylate is the generic ingredient in one branded drug marketed by Tg Theraps and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Umbralisib tosylate has sixty-eight patent family members in thirty-one countries.

Summary for UMBRALISIB TOSYLATE
International Patents:68
US Patents:8
Tradenames:1
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 9
Patent Applications: 46
DailyMed Link:UMBRALISIB TOSYLATE at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for UMBRALISIB TOSYLATE
Generic Entry Date for UMBRALISIB TOSYLATE*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for UMBRALISIB TOSYLATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tg Theraps UKONIQ umbralisib tosylate TABLET;ORAL 213176-001 Feb 5, 2021 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Tg Theraps UKONIQ umbralisib tosylate TABLET;ORAL 213176-001 Feb 5, 2021 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Tg Theraps UKONIQ umbralisib tosylate TABLET;ORAL 213176-001 Feb 5, 2021 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Tg Theraps UKONIQ umbralisib tosylate TABLET;ORAL 213176-001 Feb 5, 2021 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Tg Theraps UKONIQ umbralisib tosylate TABLET;ORAL 213176-001 Feb 5, 2021 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Tg Theraps UKONIQ umbralisib tosylate TABLET;ORAL 213176-001 Feb 5, 2021 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for UMBRALISIB TOSYLATE

Country Patent Number Title Estimated Expiration
Hong Kong 1209737 選擇性 δ抑制劑 (SELECTIVE PI3K DELTA INHIBITORS PI3K) ⤷  Sign Up
Croatia P20171610 ⤷  Sign Up
Canada 2949932 ⤷  Sign Up
Canada 2876995 NOUVEAUX INHIBITEURS SELECTIFS DE PHOSPHOINOSITIDE 3-KINASE (PI3K) DELTA (NOVEL SELECTIVE PI3K DELTA INHIBITORS) ⤷  Sign Up
Turkey 201908334 ⤷  Sign Up
Spain 2729151 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.